These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35316503)

  • 1. Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases.
    Kuwana M; Saito A; Sakamoto W; Raabe C; Saito K
    Adv Ther; 2022 May; 39(5):2222-2235. PubMed ID: 35316503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study.
    Li Q; Wallace L; Patnaik P; Alves M; Gahlemann M; Kohlbrenner V; Raabe C; Wang JR; Garry EM
    Rheumatology (Oxford); 2021 Apr; 60(4):1915-1925. PubMed ID: 33155024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States.
    Fan Y; Bender S; Shi W; Zoz D
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1539-1547. PubMed ID: 32996805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
    Funatogawa T; Narita Y; Tamura A; Mii K; Sugitani Y; Uchida T
    Mod Rheumatol; 2022 Jul; 32(4):755-760. PubMed ID: 34850080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Prevalence of Acute Exacerbation of Interstitial Lung Disease in Japanese Patients with Systemic Sclerosis.
    Tomiyama F; Watanabe R; Ishii T; Kamogawa Y; Fujita Y; Shirota Y; Sugimura K; Fujii H; Harigae H
    Tohoku J Exp Med; 2016 Aug; 239(4):297-305. PubMed ID: 27487743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
    Narita Y; Funatogawa T; Mii K; Adachi H; Tamura A; Yamakido S
    Mod Rheumatol; 2023 Apr; 33(3):525-532. PubMed ID: 35652700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study.
    Vandecasteele E; Melsens K; Vanhaecke A; Blockmans D; Bonroy C; Carton C; Deschepper E; De Keyser F; Houssiau F; Piette Y; Vanthuyne M; Verbeke K; Westhovens R; Wuyts WA; De Langhe E; Brusselle G; Smith V
    Semin Arthritis Rheum; 2021 Oct; 51(5):969-976. PubMed ID: 34403812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and risk factors of systemic sclerosis-associated interstitial lung disease in East Asia: A systematic review and meta-analysis.
    Qiu M; Nian X; Pang L; Yu P; Zou S
    Int J Rheum Dis; 2021 Dec; 24(12):1449-1459. PubMed ID: 34418313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Sclerosis and Associated Interstitial Lung Disease in Ontario, Canada: An Examination of Prevalence and Survival Over 10 Years.
    Pope JE; Quansah K; Hassan S; Seung SJ; Flavin J; Kolb M
    J Rheumatol; 2021 Sep; 48(9):1427-1434. PubMed ID: 33795325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis.
    Zhou Z; Fan Y; Thomason D; Tang W; Liu X; Zhou ZY; Macaulay D; Fischer A
    Adv Ther; 2019 May; 36(5):1100-1113. PubMed ID: 30929184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement.
    Fischer A; Kong AM; Swigris JJ; Cole AL; Raimundo K
    J Rheumatol; 2018 Feb; 45(2):235-241. PubMed ID: 29142033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence, prevalence and regional distribution of systemic sclerosis and related interstitial lung Disease: A nationwide retrospective cohort study.
    Knarborg M; Hyldgaard C; Bendstrup E; Davidsen JR; Løkke A; Shaker SB; Hilberg O
    Chron Respir Dis; 2022; 19():14799731221125559. PubMed ID: 36123773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of interstitial lung disease at initial visit may predict a favorable outcome for Japanese patients with systemic sclerosis with anti-topoisomerase I antibody.
    Hamaguchi Y; Yoshimura Y; Horii M; Fushida N; Kitano T; Sawada K; Oishi K; Maeda S; Watanabe S; Matsushita T
    J Dermatol; 2024 Jan; 51(1):62-69. PubMed ID: 37864453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis.
    Gayle A; Schoof N; Alves M; Clarke D; Raabe C; Das P; Del Galdo F; Maher TM
    Adv Ther; 2020 May; 37(5):2460-2476. PubMed ID: 32319038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis.
    Hax V; Bredemeier M; Didonet Moro AL; Pavan TR; Vieira MV; Pitrez EH; da Silva Chakr RM; Xavier RM
    Semin Arthritis Rheum; 2017 Oct; 47(2):228-234. PubMed ID: 28454677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
    Hoffmann-Vold AM; Allanore Y; Alves M; Brunborg C; Airó P; Ananieva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Kowal-Bielecka O; Riccardi A; Distler O;
    Ann Rheum Dis; 2021 Feb; 80(2):219-227. PubMed ID: 32988845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comorbidity and mortality in systemic sclerosis and matched controls: Impact of interstitial lung disease. A population based cohort study based on health registry data.
    Knarborg M; Hyldgaard C; Bendstrup E; Davidsen JR; Løkke A; Shaker SB; Hilberg O
    Chron Respir Dis; 2023; 20():14799731231195041. PubMed ID: 37596992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
    Ueda T; Sakagami T; Kikuchi T; Takada T
    Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.